Abstract
Twenty-seven patients with combat-related posttraumatic stress disorder (PTSD) entered an open, prospective, 10-week trial of fluoxetine, beginning with 20 mg/day and increasing to 80 mg/day until response was optimal or side effects prohibited dose increase. Nineteen patients completed 3 or more weeks and were included in the data analysis. Total Clinician-Administered PTSD Scale scores decreased from a mean of 64.5 at baseline to 42.7 at endpoint (F = 7.17, p < 0.001), and improvement was significant in each of the three PTSD subscales (reexperiencing, avoidance/numbing, and hyperarousal). Depression and anxiety ratings showed similar improvements, and suicidality ratings did not increase. Global improvement scores decreased from 4.0 at baseline to 2.67 at endpoint (F = 12.08, p < 0.001); however, improvement in social and occupational functioning was minimal. Appreciable improvement tended to occur after 6 weeks, suggesting that higher fluoxetine doses and/or duration than that used for depression may be indicated in this population. Panic attack frequency decreased by at least 50% in six of eight patients who kept panic diaries. The high dropout rate reflects problems with side effects, anxiety symptoms, external events, an...Continue Reading
Citations
Jan 1, 1995·Journal of Traumatic Stress·D D BlakeT M Keane
Sep 15, 1995·Biological Psychiatry·C A MorganD S Charney
Jul 31, 1996·Psychiatry Research·R WeizmanM Rehavi
Dec 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Wissam El HageCatherine Belzung
Dec 1, 1996·Biological Psychiatry·R GrossmanE L Giller
Nov 10, 1998·Biological Psychiatry·J M KentJ M Gorman
Jun 2, 1998·Comprehensive Psychiatry·S GuptaP Keller
Jan 1, 2003·Current Therapeutic Research, Clinical and Experimental·Joseph F GoldbergHyemee Han
Oct 24, 2002·Journal of Psychiatric Research·Ronald C Albucher, Israel Liberzon
Apr 11, 2003·Child Abuse & Neglect·David C WrightErin R Kraftcheck
May 5, 2001·Pharmacology & Therapeutics·S V ArgyropoulosD J Nutt
Feb 2, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Stewart D BarnettJonathan R T Davidson
Oct 16, 1999·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M Isaac
Sep 1, 1994·Journal of the American Academy of Child and Adolescent Psychiatry·B BirmaherM Brodsky
Feb 19, 2004·Drugs·Gregory M AsnisNicole L Brown
Aug 22, 2008·Croatian Medical Journal·Dragica Kozaric-Kovacic
Aug 28, 2001·Neuropharmacology·C BelzungG Griebel
Aug 5, 2008·Burns : Journal of the International Society for Burn Injuries·Rhonda RobertWalter J Meyer
Mar 1, 1994·General Hospital Psychiatry·M B Hamner
Nov 1, 1994·Baillière's Clinical Rheumatology·J I Hudson, H G Pope
Dec 17, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ferenc Martenyi, Victoria Soldatenkova
Apr 7, 2015·Psychiatry Research·Fang HanYuxiu Shi
Mar 3, 2015·Biological Psychiatry·Vasiliki MichopoulosTanja Jovanovic
Apr 1, 1997·The Australian and New Zealand Journal of Psychiatry·R D AlarconH C Eddleman
Jan 27, 2006·The Cochrane Database of Systematic Reviews·D J SteinS Seedat
Dec 16, 1998·The British Journal of Psychiatry : the Journal of Mental Science·P D LondborgC Weise
Sep 15, 2020·Health Technology Assessment : HTA·Hollie MeltonPeter Coventry
Aug 5, 2000·The Annals of Pharmacotherapy·M Cyr, M K Farrar